| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Outline of Final Research Achievements |
We had previously developed an interstrand cross-link (CL) that covalently conjugates a pair of apurinuc/apyrimidinic sites (AP sites) on complementary DNA duplex. We first examined whether the AP site-based cross-link could be applied to complementary 2′-O-methyl RNA (MeRNA) duplexes. Next, we prepared several MeRNA-based anti-miRNA oligonucleotides (AMOs) having CL duplex at the end(s) of the antisense strand, and investigated relationship between the miRNA inhibition activity and the AMO structure. Interestingly, the AMO having the CL-duplex at both terminals exhibited the highest activity and the inhibitory activity was largely affected by the positions of the duplex in AMO molecules. These results indicate the potency of the present structural basis for developing AMO as therapeutic applications.
|
